Oncogene c-Src has been found to be a potential target for the treatment of triple-negative breast cancer (TNBC). However, the therapeutic effects of the c-Src inhibitor on TNBC patients are controversial compared to those on cell lines. The molecular mechanisms of the inhibitory effects of the c-Src inhibitor on TNBC remain unclear. Herein, we showed that a specific c-Src inhibitor, PP2, was effec- and HER2 means that TNBC patients cannot benefit from endocrine therapy and targeted therapy. Thus, the discovery of effective and Lou and Yu contributed equally to this work.
specific medications for TNBC is urgently needed. Currently, a large number of potential targets have been suggested for cancer treatment, such as p53, mammalian target of rapamycin (mTOR), tyrosine kinases and epidermal growth factor receptor (EGFR). [6] [7] [8] [9] However, in clinical trials, none has yet been certified for efficient TNBC therapy. 7 Proto-oncogene c-Src is widely overexpressed in breast cancer.
It plays a vital role in multiple cellular signal transduction pathways and participates in diverse processes, such as cell growth, motility, invasion, attachment, and angiogenesis. [10] [11] [12] c-Src inhibitors can actively suppress tumor cell growth in the breast, colon, ovaries, and liver. [13] [14] [15] A large number of studies have indicated that TNBC shows higher sensitivity to the c-Src inhibitor than do other cancer subgroups. [16] [17] [18] [19] It has been proven that ER and HER2 expression levels affect the therapeutic effects of the c-Src inhibitor in breast cancer cell lines. 16 Unfortunately, patients with TNBC receive limited benefit from c-Src inhibitor treatment. [20] [21] [22] A phase II clinical trial showed only a 9.3% clinical benefit rate when a c-Src inhibitor, dasatinib, was used as a single agent. 22 This suggests that ER and HER2 expression levels are not sufficient to precisely define the resistance to the c-Src inhibitor in TNBC.
TNBC is a heterogeneous subset and shares (80%-90%) genetic abnormalities and morphological similarities with basal-like breast cancer (BLBC). 23 BLBC contains at least 2 major subtypes which are termed BLBC A and BLBC B (VIM positive). 24 Finn et al 17 reported
that the BLBC B subgroup is 85.7% (6 in 7) highly sensitive to dasatinib whereas BLBC A was 0% (0 in 9). Nevertheless, further exploration is needed to clarify the molecular mechanisms of this subtype of breast cancer.
Vimentin is a primary marker of epithelial-mesenchymal transition (EMT) and is responsible for maintaining cell shape, integrity of the cytoplasm, and stabilizing cytoskeletal interactions. It functions as an important adaptor of many crucial proteins involved in adhesion, migration, invasion, and cell signaling. 25, 26 In breast cancer, vimentin expression is upregulated during EMT, and is highly expressed in BLBC B with poor prognosis. 27 Thus, there is a need to investigate how BLBC B is highly sensitive to the c-Src inhibitors and whether vimentin is involved.
In the present study, we sought to investigate whether vimentin Table S1 . All data were normalized by GAPDH.
| CCK-8 assay
Quantity of viable cells was evaluated by using a CCK-8 kit (Dojindo, Tokyo, Japan) according to the manufacturer's protocol. Cells were trypsinized and seeded at a density of 5 9 10 3 in 96-well plates (Corning, Corning, NY, USA). After overnight incubation, PP2 was added to the medium with different concentrations for certain times.
At the end of the experiments, the medium in each well was replaced with 100 lL serum-fresh DMEM containing 10% CCK-8.
Plates were incubated at 37°C for 2 hours and then read at 450 nm with a microplate reader (Tecan Austria, Gr€ odig, Austria).
| Colony formation assay
For clonogenic assay, cells were pretreated with DMSO or (2.5, 
| Cellular migration and invasion assay
Cell migration and invasion assays were carried out using a Boyden 
| Construction of plasmids and stable transfected cell lines
Plasmid vectors and negative control were designed and packaged from GeneCopoeia (Guangzhou, China). Sequence of shRNAs is shown in Table S2 . Cells were then transfected with these plasmids using Lipofectamine 3000 (Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer's instructions. Puromycin (Amresco, Solon, OH, USA) was used to screen stable cell lines. All of the vectors were marked by enhanced GFP. 
| Tumor xenograft mouse model

| Statistical analysis
Each experiment in this study was repeated at least 3 times unless otherwise specified. All results are presented as mean AE SD. A 1-sided Student's t test was used to calculate the statistical significance between the groups in vitro whereas tumor volume was analyzed by a 2-sided Student's t test. Data were analyzed using Image-Pro Plus 6.0 software, GraphPad Prism 6.0.1 software (GraphPad, LaJolla, CA, USA) and SPSS 10.0 software (IBM, Armonk, NY, USA). P < .05 was considered statistically significant. . Cells were harvested daily for up to 7 days for CCK-8 assay. Data were normalized by vehicle control. C, Cell clones were stained with crystal violet. Number of clones in the PP2-treated group were compared with the vehicle control group. Data are presented as mean AE SD from 3 independent experiments. *P < .05 vs control; **P < .01 vs control. D, Cell cycles were measured by flow cytometry. Percentage of S phase was quantified based on 3 independent experiments. *P < .05 vs control; **P < .01 vs control. E, Four breast cancer cell lines were treated with vehicle (0.1% DMSO) or PP2 (2.5 lmol/L and 5 lmol/L) for 48 h. Cell lysates were harvested for western blotting. Signaling pathways of total Akt, phosphorylated-Akt, cyclin E1, cyclin D1 and CDK4 were detected with specific antibodies F I G U R E 3 Suppression of migration and invasion of BLBC B cells by PP2. Cells were pretreated with DMSO or PP2 (2.5 and 5 lmol/L) for 48 h. Then, cells were seeded on the A, migration upper chamber or B, invasion upper chamber in serum-free medium. The lower chamber was filled with 600 lL of 10% FBS-supplemented medium. After 20 h, migrated/invasive cells on the membrane were stained with 1% crystal violet for 15 min. Number of invading/migrating cells were then counted under a microscope and photographed (100 9 magnification). C, Cells were seeded in 6-well plates and pretreated as above. Then, the wound was scratched. Images were taken at 0 and 24 h (40 9 magnification). Migration ratios were also calculated. D, Cells were treated with DMSO or PP2 (2.5 and 5 lmol/L) for 48 h. Cell lysates were harvested. Epithelial-mesenchymal transition (EMT) markers were detected by immunoblotting with specific antibodies. *P < .01 compared with respective control; **P < .001 compared with respective control significantly inhibited an important cell growth pathway, Akt phosphorylation, in SUM1315MO2 and MDA-MB-231 cells, but not in SK-BR-3 and T-47D cells ( Figure 2E ). As for another growth pathway, RAS-MAPK, PP2 significantly inhibited phosphorylation of MAPK in MDA-MB-231 cells, but not in SK-BR-3 cells ( Figure S1 ).
In line with this, cell cycle-associated signals: cyclin E1, cyclin D1, and CDK4 were reduced in SUM1315MO2 and MDA-MB-231 cells after PP2 dosage, whereas this was without significant effects on the other 2 cell lines ( Figure 2E ). All of these results show that PP2
predominantly inhibits vimentin-positive TNBC cell proliferation.
| c-Src inhibitor prevents EMT in TNBC expressed high vimentin cell lines
c-Src is an important adaptor protein to mediate cellular focal adhesions. 16 We first examined the effect of PP2 on cell motility in 4 cell EMT-associated signaling pathways to progress aggressively. 35 Targeting EMT is a major mechanism for the c-Src inhibitor to block invasive capacity in this subset of TNBC.
Non-receptor tyrosine kinase c-Src has been found to be an essential molecule to modulate EMT through multiple pathways. Collectively, multiple molecules from the nucleus to the cytoplasm are involved in the modulation of EMT in TNBC in addition to F I G U R E 7 Therapeutic effects on xenografted mouse model after knock down of vimentin. Female BALB/c nude mice were divided into two groups (n = 12): 1 group was s.c. injected with SUM1315MO2 cells transfected with control vector; another group was s.c. injected with SUM1315MO2 cells transfected with ShRNA1. Seven days later, mice of each group were randomly divided into treatment group and control group (n = 6). Control group mice received 1% DMSO and treatment group mice received a daily i.p. injection of 10 mg/kg PP2. Mice were treated for 3 weeks in total. A, Finally, mice were killed and tumor tissues were excised. B, Tumor volume was calculated using the following formula: l 9 b 2 9 0.5, where l and b are the largest perpendicular of tumor. **P < .001 compared with the indicated group c-Src and vimentin. c-Src acts as a critical regulatory site for EMT with clinical implications for targeted therapy for TNBC patients.
This finding suggests that traditional markers for TNBC are not sufficient to precisely define this aggressive type of TNBC. Vimentin is identified as an important biomarker to subdivide TNBC with different characteristics. The present study provides an important rationale for the clinic to precisely select TNBC patients who would benefit from c-Src inhibitor treatment. Further investigation in this field will find more molecules to subdivide TNBC patients for personalized therapy.
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